Contineum Therapeutics Reports $18.7 Million Third-Quarter Net Loss

What happened

Contineum Therapeutics reported a third-quarter 2026 net loss of $18.7 million, compared with $12.8 million a year earlier. Research and development spending rose 45% to $16.0 million, led by work on PIPE-791. It reported $244.5 million in cash and marketable securities; reports give differing estimates of how long these funds may last.

Global impact / market context

Higher research spending adds to losses, while the reported cash provides funds for ongoing work. Reports differ on how long the cash may support operations, and PIPE-307 missed its main trial goal. These facts leave investors weighing current costs and trial progress.

What to watch

1. Check the company’s next reported research and development spending; it matters because spending has risen 45% from a year earlier.
2. Check for an updated estimate of how long the $244.5 million in cash and marketable securities can fund operations; reports differ between at least 12 months and through mid-2029.
3. Check for updates on PIPE-791 and the PROPEL-IPF trial, which is targeted for completion in June 2028; this matters because the work is still underway.

Affected assets

• CTNM

Evidence

• Infoway News — CTNM: PIPE-791 advances toward 2028 completion as losses grow and PIPE-307 misses its MDD endpoint 2026-11-03T21:14:26+00:00
• Infoway News — Contineum Therapeutics Reports $18.7 Million Third-Quarter Net Loss 2026-11-03T21:13:00+00:00
• Infoway News — CTNM: PIPE-791 IPF trial expands, with $244.5 million in liquidity supporting runway through mid-2029 2026-11-03T21:10:19+00:00
• Incident timeline — CTNM: PIPE-791 advances toward 2028 completion as losses grow and PIPE-307 misses its MDD endpoint
• Incident timeline — Contineum Therapeutics Reports $18.7 Million Third-Quarter Net Loss
• Incident timeline — CTNM: PIPE-791 IPF trial expands, with $244.5 million in liquidity supporting runway through mid-2029